Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Attend one of eight Highlights of ASH meetings featuring expert analysis of the 56th ASH Annual Meeting abstracts and sessions.
Obtain CME credit and a certificate of attendance for the 56th ASH Annual Meeting by April 17, 2015.
Hear top experts in hematologic malignancies discuss the latest developments in clinical care.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research.
Search a database of practicing hematologists in your area.
Help move hematology forward by supporting research, career development, and quality care and education programs.
Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.
Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.
Recognizing that leukemia cannot be conquered with a “one-size-fits-all”
approach, researchers are pursuing novel targeted therapies and combinations of
existing treatment regimens with new agents for patient populations with
historically poor prognoses, according to data presented today during the 56th
American Society of Hematology Annual Meeting and Exposition.
Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments
for blood clots and further illuminate clot risks in vulnerable populations,
such as cancer patients.
New treatment combinations and targeted therapies for
lymphoma and multiple myeloma are improving outcomes for vulnerable patient
populations with hard-to-treat disease, according to studies presented today at
the 56th American Society of Hematology Annual Meeting and Exposition.
As the 113
Congress winds down, it has become clear that this group of legislators will not be remembered as the one that permanently addressed the issues associated with Medicare physician payment. Read more to find out what may happen with the SGR in 2015.
Conference on Clinical Cancer Research brought together leaders in cancer drug
development from federal, health and regulatory agencies, academic research and
the private sector for focused discussions on critical issues surrounding the
development and regulation of cancer drugs and therapies.
The National Heart, Lung and Blood Institute (NHLBI) is now accepting applications for
Research Project Grants and
Small Business Technology Transfer Grants that will support research addressing scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. The application deadlines for these funding opportunities is February 15 and February 20, 2015, respectively.
The FDA recently indicated that it wishes to begin to provide regulatory oversight of some laboratory-developed tests. FDA is clear to indicate that it does not wish to include all tests in the regulatory process, and that it wishes to phase in this process over a period of years, starting with those tests that are most high risk. ASH is closely
reviewing this proposed guidance in order to prepare comments for submission to
Dr. Bob Löwenberg (Editor-in-Chief) and Dr. Nancy Berliner (Deputy Editor-in-Chief) have combined efforts to identify some of the most outstanding Blood articles that have appeared either in print or online during the two-month interval between issues of The Hematologist. The goal is to underscore the remarkable research that is published in Blood and to highlight the exciting progress that is being made in the field.
Dr. Bertuch and Dr. Kurre examine the need for improvement in how acquired aplastic anemia is both diagnosed and treated in the United States.
This fall, ASH will begin publishing a monthly news magazine specifically designed to appeal to clinical practitioners in hematology and oncology. ASH Clinical News will provide timely updates in the field by reporting on key medical meetings, clinical trials, innovative technology, and influential papers in the literature.
Dr. Gilbert White chronicles his involvement in the HIV and HCV epidemics that devastated the hemophilia population in the 1980s, highlighting the power of science and the resilience of patients, physicians, and scientists, who faced adversity and triumphed.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology